59452-87-8

Upstream product

• 105-39-5 chloroacetic acid ethyl ester 
• 121-89-1 3-Nitroacetophenone 
• 586-39-0 1-nitro-3-vinyl-benzene 
• 201230-82-2 carbon monoxide 
• 102872-35-5 2-(3-nitrophenyl)propan-1-ol 

Downstream Products

• 844904-03-6 2-methyl-5-{4-[2-(3-nitrophenyl)propyl]-1-piperazinyl}quinoline 
• 1296698-85-5 (S)-di-tert-butyl 1-(2-(3-nitrophenyl)-1-oxopropan-2-yl)hydrazine-1,2-dicarboxylate 
• 1369965-77-4 C₁₆H₁₅NO₃S₂ 
• 40460-77-3 3-Nitro-hydratropaaldehyd-benzylimin 
• 40460-64-8 2-(3-Nitrophenyl)-propionaldehyd-methylimin 
• 40460-75-1 (4-Methoxy-phenyl)-[(E)-2-(3-nitro-phenyl)-propenyl]-amine 
• 102872-35-5 2-(3-nitrophenyl)propan-1-ol 

Relevant academic research and scientific papers

Highly selective hydroformylation of vinylarenes to branched aldehydes by [Rh(cod)Cl]2 entrapped in ionic liquid modified silica sol-gel

A co-entrapped mixture of [Rh(cod)Cl]2 and Na[Ph 2P-3-(C6H4SO3)] within a silica sol-gel matrix modified with ca. 5% of 1-butyl-3-[3-(trimethoxysilyl)propyl] imidazolium chloride catalyzes, in n-heptane, the hydroformylation of a variety of vinylarenes. At 50°C and under 6.9 bar each of H2 and CO the reaction is high-yielding and highly selective. Non-hindered substrates give >95 % of branched aldehydes and only 5% of the linear isomers. The ceramic catalyst is leach-proof and recyclable. It does not lose its high catalytic activity and selectivity for at least four runs. The selectivity depends on the pressure of the gases, the temperature and the solvent. The electronic nature has no influence on the selectivity, but the latter is diminished by steric effects. Upon omission of the sol-gel component, the catalyst deteriorates and practically loses its activity after the first half-life of the reaction. In the absence of the ionic liquid, the catalyst undergoes substantial leaching. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.

Intermetallic Nanocatalyst for Highly Active Heterogeneous Hydroformylation

Hydroformylation is an imperative chemical process traditionally catalyzed by homogeneous catalysts. Designing a heterogeneous catalyst with high activity and selectivity in hydroformylation is challenging but essential to allow the convenient separation and recycling of precious catalysts. Here, we report the development of an outstanding catalyst for efficient heterogeneous hydroformylation, RhZn intermetallic nanoparticles. In the hydroformylation of styrene, it shows three times higher turnover frequency (3090 h-1) compared to the benchmark homogeneous Wilkinson's catalyst (966 h-1), as well as a high chemoselectivity toward aldehyde products. RhZn is active for a variety of olefin substrates and can be recycled without a significant loss of activity. Density functional theory calculations show that the RhZn surfaces reduce the binding strength of reaction intermediates and have lower hydroformylation activation energy barriers compared to pure Rh(111), leading to more favorable reaction energetics on RhZn. The calculations also predict potential catalyst design strategies to achieve high regioselectivity.

Synthesis of tetra-pincer nickel(ii) and palladium(ii) complexes of resorcin[4]arene-octophosphinite [Res(OPR2)8] and rhodium-catalyzed regioselective hydroformylation reaction

The condensation reaction of resorcinol with pentanal yielded resorcin[4]arene 1 which on bromination using N-bromosuccinimide at room temperature produced tetra-bromide derivative 2. The reactions of 2 with chlorodiphenylphosphine and o-phenylenephosphoro-chloridite yielded octaphosphinite 3 (hereafter referred to as octaphos) and octaphosphite 4, respectively. The reactions of 3 with Ni(COD)2 or Pd2(dba)3·CHCl3 in appropriate molar ratios yielded tetra-pincer complexes 5 and 6, respectively. The structures of both the complexes were established by single crystal X-ray diffraction studies. The resorcin[4]arene backbone adopts a boat structure in these complexes. Typically, the Rh-catalyzed hydroformylation of styrene prevalently delivers a branched (b) chiral aldehyde. A unique resorcin[4]arene skeleton based octaphos 3 was employed in the Rh-catalyzed hydroformylation of styrene. The hydroformylation of styrene with a metal to ligand ratio of 1:1 (M:L) was found to be regioselective, producing a linear (l) aldehyde as a major product with 100% conversion in 3 h. The l:b ratio surprisingly increased when the ortho positions of styrene were populated by methyl and chloro substituents. The hydroformylation of p-nitro styrene triggered a remarkably high linear:branched aldehyde ratio of 2.4 (71% linear aldehyde) despite its electron withdrawing nature. The highest linear selectivity of 97% (l:b ratio 27.8) was achieved in the case of 2,4,6-trimethylstyrene.

FUNCTIONALIZED MAGNETIC NANOPARTICLE, A CATALYST, A METHOD FOR FORMING C-C BONDS

A functionalized magnetic nanoparticle including an organometallic sandwich compound and a magnetic metal oxide. The functionalized magnetic nanoparticle may be reacted with a metal precursor to form a catalyst for various C—C bond forming reactions. The catalyst may be recovered with ease by attracting the catalyst with a magnet.

Magnetic nanoparticle-supported ferrocenylphosphine: A reusable catalyst for hydroformylation of alkene and Mizoroki-Heck olefination

We present dopamine (dop) conjugated bis(diphenylphosphino)ferrocenylethylamine (BPPFA) functionalized magnetic nanoparticles (Fe3O4). A ferrocene ({η5-C5H4-PPh2}Fe{η5-C5H3-1-PPh2-2-CH(Me)NH-CH2-CH2-4Ph-1,2-OH}) ligand (dop-BPPF) has been prepared by reaction of (1-[1′,2-bis(diphenylphosphino)-ferrocenyl]ethyl acetate) and dopamine hydrochloride to form dop-BPPF, which was characterized by NMR, IR, FTIR, EA and FAB-MS. This ligand was anchored on ultrasmall (6-8 nm) magnetic nanoparticles (MNP) to yield Fe3O4@dop-BPPF. The resulting ferrocenylphosphine on magnetic nanoparticles was characterized by SEM, EDS, XRD, TEM, TGA, and VSM. The magnetic nature of the materials was investigated. Fe3O4@dop-BPPF exhibits very high catalytic activity for the Pd-catalyzed Mizoroki-Heck reaction and exceptionally high regioselectivity for the Rh-catalyzed hydroformylation reaction with branched aldehydes (up to > 99%). The potential of this Fe3O4@dop-BPPF as a reusable catalyst has been studied for the Mizoroki-Heck reaction, and this catalyst was robustly active even after eleven consecutive cycles.

The rhodium complex of bis(diphenylphosphinomethyl)dopamine-coated magnetic nanoparticles as an efficient and reusable catalyst for hydroformylation of olefins

A new bis(diphenylphosphinomethyl)dopamine (bpd) ligand has been prepared and anchored on the surface of magnetic nanoparticles (MNPs). The obtained ligand and the surface functionalized nanoparticles of type MNP@bpd have been characterized by various analytical techniques, such as NMR, IR, TEM, XRD, and VSM. TEM shows homogeneous distribution of the particles with the size ranging 5-7 nm. XRD Rietveld analysis confirms the formation of a pure and single Fe3O4 phase with high crystallinity. The ligands anchored on the magnetic nanoparticle surface have been confirmed by the shift of the characteristic Fe-O vibration band in the FT-IR spectrum, and have been supported by the stepwise weight loss in TGA as a function of temperature. The phosphorus content determined by ICP-MS is approximately 0.39 mmol of phosphine per gram of the nanoparticles. Magnetization-field curves recorded at room temperature reveal superparamagnetic behavior. MNP@bpd materials have proven to be excellent catalysts after in situ addition of the rhodium (Rh) metal precursor for the hydroformylation reaction of styrene and its derivatives. The extent of reusability of the catalyst has been tested and was found to be active even after seven consecutive cycles.

QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Sulfonamide-containing heterocyclic compounds

The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or: (wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is ═C(D)— (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is ═C(D)—, nitrogen atom, —CH2—, oxygen atom or —CO—; Z is a single bond or —CO—NH—; and R1 is hydrogen atom, etc.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.